Pharmacological and analytical interference in hormone assays for diagnosis of adrenal incidentaloma.


Journal

Annales d'endocrinologie
ISSN: 2213-3941
Titre abrégé: Ann Endocrinol (Paris)
Pays: France
ID NLM: 0116744

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 30 03 2018
revised: 27 09 2018
accepted: 19 11 2018
pubmed: 26 8 2019
medline: 6 2 2020
entrez: 26 8 2019
Statut: ppublish

Résumé

Adrenal incidentaloma refers to an asymptomatic adrenal mass detected through an imaging procedure performed for reasons unrelated to adrenal dysfunction or suspected dysfunction. In general, adrenal incidentalomas are non-functioning adrenal adenomas, but in some cases, may require therapeutic intervention: eg., adrenocortical carcinoma, pheochromocytoma, primary aldosteronism, cortisol hypersecretion, or adrenal insufficiency. Hormone assessment is crucial to characterize adrenal incidentaloma. Nowadays, various hormone assay methods are available, such as immunoassay and mass spectrometry. However, there are several pitfalls that should be considered: e.g., circadian rhythm, gender/age dependency, preanalytical and analytical issues, and drug interactions. Pharmacological or analytical interference can lead to false serum concentrations and may result in misinterpretation of results and thus inappropriate treatment. The purpose of this review was to study the main interferences that may be observed in the different tumor types of adrenal incidentalomas in order to help physicians in their clinical decision-making and for the overall benefit of patients.

Identifiants

pubmed: 31445667
pii: S0003-4266(19)30021-6
doi: 10.1016/j.ando.2018.11.006
pii:
doi:

Substances chimiques

Hormones 0
Pharmaceutical Preparations 0
Hydrocortisone WI4X0X7BPJ

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

250-258

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Antoine-Guy Lopez (AG)

Institute for Clinical Biology-General Biochemistry Unit, Rouen University Hospital, 76000 Rouen, France. Electronic address: antoine-guy.lopez@chu-rouen.fr.

François Fraissinet (F)

Institute for Clinical Biology-General Biochemistry Unit, Rouen University Hospital, 76000 Rouen, France.

Herve Lefebvre (H)

Department of Endocrinology, Rouen University Hospital, 76000 Rouen, France; Inserm Unit U1239, Laboratory of Differentiation & Neuronal and Neuroendocrine Communication, IRIB, Normandie University, 76130 Mont-Saint-Aignan, France.

Valéry Brunel (V)

Institute for Clinical Biology-General Biochemistry Unit, Rouen University Hospital, 76000 Rouen, France.

Frédéric Ziegler (F)

Institute for Clinical Biology-General Biochemistry Unit, Rouen University Hospital, 76000 Rouen, France; Inserm U1073, Laboratory of Digestive Tract Environment and Nutrition ADEN, Normandie University, 76000 Rouen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH